Z Stock Recent News

Investors are betting that a big Fed rate-cutting cycle will lower costs for homebuyers and loosen up the real estate market. Zillow would benefit from growing home sales volumes.

Orphe Divounguy, Zillow, joins 'Fast Money' to talk the impact of rate cuts on housing affordability.

Zillow Group (Z) is well positioned to benefit from lower U.S. mortgage rates, Wedbush analysts said Monday.

ZG enhances its AI native natural language search engine to streamline the home buying process.

SEATTLE , Sept. 3, 2024 /PRNewswire/ -- Zillow Group, Inc. (Nasdaq: Z and ZG), which is transforming the way people buy, sell, rent and finance homes, today announced that it will present at the Goldman Sachs Communacopia + Technology Conference on Sept.

Tulloss oversees Zillow's agent sales team, which provides real estate agents advertising and software solutions to power their businesses SEATTLE , Aug. 22, 2024 /PRNewswire/ -- Zillow Group, Inc. (Nasdaq: Z and ZG), which is transforming the way people buy, sell, rent and finance homes, today announced Soumya Tulloss has joined as senior vice president of agent sales, doubling down on the Company's commitment to help real estate agents power their business with Zillow.  Zillow Group's purpose is to make home a reality for more and more people.

Seattle, WA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SEATTLE, August 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ (QLHC), today announced the first patient has been dosed in their clinical trial evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology with a focus on breast cancer.

SEATTLE, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ (QLHC), today announced the first patient has been dosed in their clinical trial evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology with a focus on breast cancer.

Shares of Zillow (Z) have begun to rise as the company posted its latest quarterly results, beating analyst estimates on both the top and bottom line while also naming a new CEO, Jeremy Waxman, who previously served as the company's COO. Zillow Group CEO Jeremy Wacksman joins Market Domination to give insight into his new position and what lies ahead for the company.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.